Sheldon Goldberg, MD
Physical Medicine & Rehabilitation · Lakewood, CONPI 1184725947
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Amgen at 33.2% of the total. Reporting peaked in 2019 at $1,901 and has fallen 77.6% since, to $426 in 2025. Among physical medicine & rehabilitation clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 87 payments — averaging $71.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Biohaven Pharmaceuticals, Inc.$750
- Pfizer$366
- Biohaven Pharmaceutical Holding Company Ltd.$349
- Lilly USA, LLC$336
- Neurocrine Biosciences, Inc.$291
- plus $2K from 18 others
What the payments were for
- Grants$671%
- Food & beverage$6,13299%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 20 | $2,059 |
| Biohaven Pharmaceuticals, Inc. | 11 | $750 |
| Pfizer | 5 | $366 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $349 |
| Lilly USA, LLC | 4 | $336 |
| Neurocrine Biosciences, Inc. | 5 | $291 |
| Acadia Pharmaceuticals Inc | 4 | $289 |
| AbbVie | 3 | $220 |
| Heartflow, Inc. | 3 | $193 |
| Assertio Therapeutics, Inc. | 2 | $172 |
| Avanir Pharmaceuticals, Inc. | 2 | $166 |
| Acell, Inc. | 2 | $147 |
| Eisai Inc. | 1 | $125 |
| Novartis | 6 | $122 |
| Vanda Pharmaceuticals Inc. | 1 | $119 |
| Otsuka America Pharmaceutical, Inc. | 1 | $113 |
| Tanabe Pharma America, Inc. | 1 | $99 |
| Scilex Pharmaceuticals Inc. | 6 | $93 |
| Boston Scientific | 1 | $67 |
| Currax Pharmaceuticals LLC | 1 | $48 |
| Almatica Pharma LLC | 2 | $35 |
| Vertex | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,199 in reported general payments places this provider in the 90th percentile of 199 physical medicine & rehabilitation providers in Colorado.
See all physical medicine & rehabilitation providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 99 | $29,627 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,975 |
| RenvelaSevelamer Carbonate | 14 | $4,272 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $3,185 |
| FarxigaDapagliflozin Propanediol | 11 | $2,944 |
| Clonidine | 30 | $1,862 |
| Celecoxib | 12 | $1,361 |
| Atorvastatin Calcium | 128 | $1,125 |
| Levothyroxine Sodium | 157 | $1,023 |
| Tamsulosin Hcl | 66 | $843 |
| Gabapentin | 49 | $781 |
| Metoprolol Succinate | 59 | $780 |
| Amlodipine Besylate | 95 | $561 |
| Baclofen | 27 | $559 |
| Diclofenac Sodium | 13 | $458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $366 | $29,62799 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 199 physical medicine & rehabilitation providers in Colorado.
Other physical medicine & rehabilitation in Lakewood
- Drew TrainorGreenwood Village$320K
- William ScelzaEnglewood$16K
- Aakash ThakralGreeley$14K
- Alan WeintraubEnglewood$10K
- Ryan FlowersGreeley$10K
- Kristina BarberParker$9K
- Gin-Ming HsuDenver$8K
- Esther YoonLittleton$7K
- Cliff GronsethBoulder$7K
- Colton MalesovasLongmont$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.